<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17692" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Antifungal Antibiotics</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McKeny</surname>
            <given-names>Patrick T.</given-names>
          </name>
          <aff>Orange Park Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nessel</surname>
            <given-names>Trevor A.</given-names>
          </name>
          <aff>MSU College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zito</surname>
            <given-names>Patrick M.</given-names>
          </name>
          <aff>University of Miami; Miller School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick McKeny declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Trevor Nessel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Patrick Zito declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>7</day>
          <month>3</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17692.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Fungi are unicellular or multi-cellular eukaryotic organisms that exist in all environments worldwide. While most fungi do not play a significant role in human disease, there are several hundred fungi that do, resulting in fungal infection or disease. Fungal infections (mycoses) range from common benign infections like 'jock itch' to serious, life-threatening infections such as cryptococcal meningitis. Antifungal antimicrobials are one drug class that can combat these mycoses. This activity reviews the indications, contraindications, activity, adverse events, and other critical elements of antiemetic use of antifungal antimicrobials in the clinical setting as relates to the essential points needed by members of an interprofessional team managing the care of patients who present with mycotic infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Summarize the mechanism of action of various antifungal antimicrobials.</p></list-item><list-item><p>Identify the approved indications and contraindications of antifungal antimicrobials.</p></list-item><list-item><p>Review the adverse events and toxicity of antifungal antimicrobials.</p></list-item><list-item><p>Explain interprofessional team strategies for improving care coordination and communication with antifungal antimicrobial therapy to treat mycotic infections to achieve optimal patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17692&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17692">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17692.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Fungi are unicellular or multi-cellular eukaryotic organisms that exist in all environments worldwide. From fungi visible to the naked eye, such as mushrooms, to microscopic yeasts and molds, they exist in many forms. While most fungi do not play a significant role in human disease, there are several hundred fungi that do, resulting in fungal infection or disease. Fungal infections (mycoses) range from common benign infections like&#x000a0;'jock itch' to serious, life-threatening infections such as cryptococcal&#x000a0;meningitis. The term 'antifungals' encompasses all chemical compounds, pharmacologic agents, and natural products used to treat mycoses.</p>
        <p>Clinically, fungal infections are best categorized first according to the site and extent of the infection, then the route of acquisition, and finally, the virulence of the causative organism. These&#x000a0;classifications are essential when determining the most effective treatment regimen for a particular&#x000a0;mycosis.&#x000a0;Mycoses classify as local (superficial, cutaneous, subcutaneous) or systemic (deep, bloodborne). The acquisition of the fungal infection is either&#x000a0;an exogenous (airborne/inhalation, cutaneous exposure, percutaneous inoculation) or an endogenous process (normal flora or reactivated infection). The virulence of the organism is classified as either a primary infection (disease arising in a healthy host) or opportunistic infection (disease arising in human hosts that have a compromised immune system or other defenses).<xref ref-type="bibr" rid="article-17692.r1">[1]</xref></p>
        <p>Antifungal&#x000a0;drugs represent a pharmacologically diverse group of&#x000a0;drugs that are crucial components in the modern medical management of mycoses. While antimycotic pharmacology has advanced significantly, particularly in the last three decades, common invasive fungal infections still carry a high mortality rate: <italic toggle="yes">Candida albicans</italic> (approximately 20 to 40% mortality),&#x000a0;<italic toggle="yes">Aspergillus fumigatus</italic> (approximately 50 to 90%), <italic toggle="yes">Cryptococcus neoformans</italic> (approximately 20 to 70%).<xref ref-type="bibr" rid="article-17692.r2">[2]</xref><xref ref-type="bibr" rid="article-17692.r3">[3]</xref> Amphotericin B deoxycholate, a polyene antibiotic, was the first antimycotic agent introduced in 1958 to treat systemic mycoses. While this drug is an effective agent, the demand for other efficacious topical, oral, and intravenous was apparent. Griseofulvin was introduced in 1959, representing the second class of antifungals. The next significant introduction would not take place until 1971, when the antimetabolite drug flucytosine entered the market. Azoles first became available in 1973 with the arrival of clotrimazole; with additional azoles that have the pharmaceutical industry has rolled out over the past five decades: miconazole (1979), ketoconazole (1981), fluconazole (1990), itraconazole (1992), voriconazole (2002), posaconazole (2006), and most recently isavuconazonium (2015).<xref ref-type="bibr" rid="article-17692.r4">[4]</xref>&#x000a0;Terbinafine, an allylamine antifungal, was FDA approved in 1996 but has indications for the treatment of local, non-systemic fungal infections. The next breakthrough in systemic therapy would have a basis in amphotericin B lipid formulations, which have more favorable side effect profiles. Following lipid formulations of azoles, a new class of antifungal agents that are highly effective in treating some systemic mycoses, are the recently developed echinocandins class. While the echinocandins demonstrate less renal toxicity than amphotericin B, they cause significant hepatotoxicity and are more expensive than azoles; this effectively relegates this class to second or third-line agents.<xref ref-type="bibr" rid="article-17692.r5">[5]</xref>&#x000a0;Mechanistically, antifungal agents are diverse, yet due to the alarming and rapid increase in drug-resistant systemic fungal infections, new agents are necessary more than ever.<xref ref-type="bibr" rid="article-17692.r6">[6]</xref><xref ref-type="bibr" rid="article-17692.r7">[7]</xref><xref ref-type="bibr" rid="article-17692.r8">[8]</xref><xref ref-type="bibr" rid="article-17692.r9">[9]</xref> This discussion will focus on the currently available antifungal agents.<xref ref-type="bibr" rid="article-17692.r10">[10]</xref><xref ref-type="bibr" rid="article-17692.r11">[11]</xref><xref ref-type="bibr" rid="article-17692.r12">[12]</xref><xref ref-type="bibr" rid="article-17692.r13">[13]</xref></p>
        <p>Common, medically relevant&#x000a0;fungal infections include, but are not limited to,&#x000a0;the following&#x000a0;(<bold>Fungal Infection</bold> - <italic toggle="yes">Typical causative organisms)</italic><xref ref-type="bibr" rid="article-17692.r14">[14]</xref><xref ref-type="bibr" rid="article-17692.r15">[15]</xref><xref ref-type="bibr" rid="article-17692.r16">[16]</xref><xref ref-type="bibr" rid="article-17692.r17">[17]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Aspergillosis</bold> - <italic toggle="yes">Aspergillus&#x000a0;fumigatus, A. flavus</italic></p>
          </list-item>
          <list-item>
            <p><bold>Blastomycosis</bold> - <italic toggle="yes">Blastomyces</italic>&#x000a0;<italic toggle="yes">dermatitidis</italic></p>
          </list-item>
          <list-item>
            <p><bold>Candidiasis</bold> - <italic toggle="yes">Candida albicans, C. glabrata, C. krusei, C. parasilosis, C. tropicalis</italic></p>
          </list-item>
          <list-item>
            <p>
<bold>Chromoblastomycosis (Chromomycosis)</bold>
<italic toggle="yes"> - Cladosporium carrionii, Phialophora verrucosa,&#x000a0;Fonsecaea pedrosoi</italic>
</p>
          </list-item>
          <list-item>
            <p><bold>Coccidioidomycosis</bold>&#x000a0;- <italic toggle="yes">Coccidioides imitis, C. posadasii</italic></p>
          </list-item>
          <list-item>
            <p><bold>Cryptococcosis</bold> - <italic toggle="yes">Cryptococcus neoformans, C. gattii</italic></p>
          </list-item>
          <list-item>
            <p><bold>Dermatophytosis (Tinea)</bold>&#x000a0;- <italic toggle="yes">Microsporum spp., Epidermophytum spp., Trichophyton spp.</italic></p>
          </list-item>
          <list-item>
            <p><bold>Fusariosis</bold> - <italic toggle="yes">Fusarium oxysporum,</italic>
<italic toggle="yes">F.</italic>
<italic toggle="yes">proliferatum, F. verticillioides</italic></p>
          </list-item>
          <list-item>
            <p><bold>Histoplasmosis</bold> - <italic toggle="yes">Histoplasma capsulatum</italic></p>
          </list-item>
          <list-item>
            <p><bold>Mucormycosis (Zygomycosis)&#x000a0;</bold>- <italic toggle="yes">Mucor spp., Rhizopus spp.</italic></p>
          </list-item>
          <list-item>
            <p><bold>Paracoccidioidomycosis&#x000a0;</bold>- <italic toggle="yes">Paracoccidioides brasiliensis</italic></p>
          </list-item>
          <list-item>
            <p><bold>Pneumocystis pneumonia</bold> - <italic toggle="yes">Pneumocystis jirovecii </italic>(formerly called <italic toggle="yes">P. carinii</italic>)*
<list list-type="bullet"><list-item><p>*While this is an essential and prevalent fungal disease, it is not treated with typical antifungal agents.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Sporotrichosis</bold> - <italic toggle="yes">Sporothrix schenckii</italic></p>
          </list-item>
          <list-item>
            <p><bold>Tinea (Pityriasis) Versicolor</bold> -<italic toggle="yes">&#x000a0;Malassezia furfur </italic>(also called <italic toggle="yes">Pityrosporum orbiculare), M. globosa</italic></p>
          </list-item>
        </list>
        <p>
<bold>Antifungal Drug Classification and Common Specific Drugs</bold>
<xref ref-type="bibr" rid="article-17692.r4">[4]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Loss of cell membrane integrity:</bold>
<list list-type="bullet"><list-item><p><bold>Polyenes</bold>: amphotericin B deoxycholate, liposomal amphotericin B, amphotericin B lipid complex, nystatin</p></list-item><list-item><p><bold>Azoles:&#x000a0;</bold>ketoconazole, miconazole, clotrimazole, itraconazole, isavuconazonium sulfate (isavuconazole), fluconazole, voriconazole, posaconazole</p></list-item><list-item><p><bold><bold>Allylamines</bold>:</bold> terbinafine</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Loss of cell wall integrity:</bold>
<list list-type="bullet"><list-item><p><bold>Echinocandins</bold>: anidulafungin, caspofungin, micafungin</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold><bold>Mitotic</bold>
<bold>Inhibitors</bold>:</bold> griseofulvin</p>
          </list-item>
          <list-item>
            <p><bold>Antimetabolites</bold>: flucytosine</p>
          </list-item>
          <list-item>
            <p>
<bold>Ciclopirox</bold>
</p>
          </list-item>
          <list-item>
            <p><bold>Quinoline Derivatives</bold>: iodoquinol, clioquinol</p>
          </list-item>
          <list-item>
            <p><bold>Potassium Iodide</bold>: saturated solution of potassium iodide (SSKI)</p>
          </list-item>
          <list-item>
            <p>
<bold>Zinc pyrithione</bold>
</p>
          </list-item>
        </list>
        <p>
<bold>Indications</bold>
<xref ref-type="bibr" rid="article-17692.r18">[18]</xref>
<xref ref-type="bibr" rid="article-17692.r19">[19]</xref>
<xref ref-type="bibr" rid="article-17692.r20">[20]</xref>
<xref ref-type="bibr" rid="article-17692.r21">[21]</xref>
</p>
        <p><bold>Amphotericin B deoxycholate (AMB-d)</bold> is FDA indicated for treating life-threatening or potentially life-threatening fungal infections: aspergillosis, cryptococcosis, blastomycosis, systemic candidiasis, coccidioidomycosis, histoplasmosis, and mucormycosis. AMB-d is also approved for&#x000a0;treating the parasitic disease American mucocutaneous leishmaniasis. AMB-d has an off-label use for esophageal candidiasis (both HIV infected and non-HIV infected adults and adolescents; HIV-exposed and or infected infants and children), fluconazole-refractory oropharyngeal candidiasis, candidal endophthalmitis, candidal urinary tract infections, visceral leishmaniasis, and ophthalmic aspergillosis.&#x000a0;</p>
        <p><bold>Liposomal amphotericin</bold>
<bold>B (L-AMB)</bold> has FDA approval to treat systemic&#x000a0;aspergillosis, candidiasis, and cryptococcosis in&#x000a0;patients with renal function impairment and patients refractory to AMB-d therapy. Additionally, L-AMB is an empiric antifungal therapy in febrile neutropenic patients and HIV-infected patients with cryptococcal meningitis. Visceral leishmaniasis is a&#x000a0;parasitic infection also treated with this agent. L-AMB has extensive off-label usage for patients infected or exposed to HIV, including candidiasis, coccidioidomycosis, cryptococcosis, and histoplasmosis.<xref ref-type="bibr" rid="article-17692.r22">[22]</xref><xref ref-type="bibr" rid="article-17692.r23">[23]</xref><xref ref-type="bibr" rid="article-17692.r24">[24]</xref><xref ref-type="bibr" rid="article-17692.r25">[25]</xref></p>
        <p><bold>Amphotericin B lipid complex (ABLC)</bold>, like L-AMB, is indicated in treating invasive mycoses in patients unable to tolerate AMB-d. Off-label use of ABLC&#x000a0;is an indicated agent in HIV infected patients with coccidioidomycosis, cryptococcal meningitis, and histoplasmosis; empiric therapy for candidiasis and neutropenic fever; and in the treatment of the parasitic infection visceral leishmaniasis.<xref ref-type="bibr" rid="article-17692.r26">[26]</xref><xref ref-type="bibr" rid="article-17692.r27">[27]</xref><xref ref-type="bibr" rid="article-17692.r28">[28]</xref><xref ref-type="bibr" rid="article-17692.r29">[29]</xref></p>
        <p><bold>Nystatin</bold> has approval as an oral "swish-and-swallow" suspension for the treatment of cutaneous, mucocutaneous, and oral <italic toggle="yes">Candida</italic> infections. Topically, nystatin has approval for treating mucocutaneous and cutaneous infections with <italic toggle="yes">Candida spp.</italic> (most commonly <italic toggle="yes">C. albicans).</italic></p>
        <p><bold>Ketoconazole</bold>, when applied topically, has been approved for treating tinea corporis, tinea cruris, tinea&#x000a0;pedis, tinea versicolor, cutaneous candidiasis, and seborrheic dermatitis. Off-label, topical ketoconazole is used to treat several oral candidal pathologies, including&#x000a0;chronic mucocutaneous candidiasis and oral thrush. Ketoconazole is also a systemic agent, which has approval for treating blastomycosis, coccidioidomycosis, chromomycosis, histoplasmosis, and paracoccidioidomycosis. Off-label oral ketoconazole treatment is used to treat Cushing syndrome and prostate cancer.</p>
        <p>Topical <bold>miconazole</bold> is approved to treat cutaneous and mucocutaneous mycoses, particularly vulvovaginal candidiasis. Oral formulations of miconazole are indicated for oropharyngeal candidiasis.</p>
        <p>In topical forms, <bold>clotrimazole</bold> is approved to treat tinea corporis, tinea pedis, tinea versicolor, cutaneous candidiasis, and vaginal yeast infections. The indication&#x000a0;for the use of oral clotrimazole is the treatment of oropharyngeal candidiasis.</p>
        <p><bold>Itraconazole</bold> is an oral drug. It is approved to treat aspergillosis (pulmonary and extrapulmonary), blastomycosis (pulmonary and extrapulmonary), and histoplasmosis (systemic/disseminated not involving the CNS, cavitary pulmonary histoplasmosis) in both immunocompromised and immunocompetent patients. In immune-competent patients, this drug is also approved to treat oropharyngeal candidiasis, esophageal candidiasis, and onychomycosis (toenail or fingernail).</p>
        <p><bold>Fluconazole</bold> indications include the treatment of esophageal, oropharyngeal, peritoneal, urinary tract, and vaginal candidiasis &#x02014; additionally, fluconazole treats systemic&#x000a0;fungal infections, including candidemia, candida pneumonia, and cryptococcal meningitis. Fluconazole serves as a first-line agent in prophylaxis for mycosis in allogeneic hematopoietic stem cell transplant patients. Off-label, fluconazole has a variety of applications, including blastomycosis, empiric antifungal therapy in non-neutropenic ICU patients, candida prophylaxis&#x000a0;(ICU with a high risk of invasive <italic toggle="yes">Candida spp.,</italic> transplant patients), and tinea.</p>
        <p><bold>Voriconazole</bold> has approval for the&#x000a0;following indications: invasive aspergillosis, candidemia in non-neutropenic patients, esophageal candidiasis, and disseminated candidiasis. This drug also treats life-threatening mycoses from fungi like <italic toggle="yes">Fusarium spp.&#x000a0;</italic>Off-label uses for voriconazole are mostly aimed at prophylactic and suppression therapy of fungal infections, including but not limited to&#x000a0;aspergillosis, candidiasis, coccidioidomycosis, hematopoietic stem cell transplant patients with or without graft versus host disease, acute myelogenous leukemia, empiric therapy in neutropenic fever, and myelodysplastic syndrome.</p>
        <p><bold>Isavuconazole</bold> is approved to treat invasive aspergillosis and invasive mucormycosis in adult populations.&#x000a0;</p>
        <p><bold>Posaconazole</bold> has approval for prophylaxis of both invasive aspergillosis and invasive candidiasis. Additionally, posaconazole is used to treat oropharyngeal candidiasis, typically&#x000a0;for patient populations refractory to treatment with fluconazole and itraconazole.</p>
        <p><bold>Terbinafine</bold> has approvals as both a topical and systemic (oral) agent. Topical terbinafine is approved to treat tinea (pedis, cruris, and corporis). When administered orally, indications for this drug include the systemic treatment of onychomycosis (tinea unguium) and tinea capitis. Common off-label use of oral formulations includes the treatment of tinea (cruris, corporis, penis, and manuum) as well as lymphocutaneous and cutaneous sporotrichosis.&#x000a0;</p>
        <p>The echinocandin <bold>anidulafungin&#x000a0;</bold>is only given intravenously. It has approval for the treatment of <italic toggle="yes">Candida spp.</italic> infections (esophageal candidiasis, candidemia, <italic toggle="yes">Candida spp.</italic> peritonitis, and intrabdominal abscesses when <italic toggle="yes">Candida spp.</italic> is grown in culture or the suspected organism).</p>
        <p><bold>Caspofungin</bold> is only approved and administered intravenously. This agent has approval for treating invasive aspergillosis&#x000a0;for patient populations refractory to amphotericin B and itraconazole. Caspofungin has also received approval in the treatment of <italic toggle="yes">Candida</italic>
<italic toggle="yes">spp.</italic> infections (candidemia, esophageal, intra-abdominal abscess, peritonitis, and empiric therapy in neutropenic patients). Off-label this agent is utilized as an adjunct in other severe <italic toggle="yes">Candida</italic>
<italic toggle="yes">spp.</italic> infections not listed above.</p>
        <p><bold>Micafungin&#x000a0;</bold>is also only approved for intravenous administration in treating esophageal candidiasis, prophylaxis of <italic toggle="yes">Candida</italic>
<italic toggle="yes">spp.</italic> infections, candidemia, <italic toggle="yes">Candida</italic>
<italic toggle="yes">spp.</italic> peritonitis, <italic toggle="yes">Candida</italic>
<italic toggle="yes">spp.</italic> abscesses, and disseminated candidiasis.&#x000a0;</p>
        <p><bold>Griseofulvin</bold> is only approved as a systemic (oral) agent and is indicated for the treatment of dermatophytoses of the skin, hair, and nails, which is severe or refractory to topical therapy. Specifically, this drug treats tinea (corporis, pedis, cruris, barbae, capitis, and unguium).</p>
        <p><bold>Flucytosine</bold> has attained approval as an adjunct antifungal agent in treating systemic <italic toggle="yes">Candida spp.</italic> or <italic toggle="yes">Cryptococcus spp.</italic> infections. Off-label, flucytosine is utilized in treating pediatric endocarditis caused by <italic toggle="yes">Aspergillus spp.</italic></p>
        <p><bold>Ciclopirox</bold> is FDA indicated for the topical treatment of tinea corporis, tinea pedis, tinea cruris, tinea unguium (onychomycosis), tinea (pityriasis) versicolor, and the <italic toggle="yes">Candida spp.</italic> infection moniliasis.</p>
        <p><bold>Iodoquinol</bold> (discontinued use in the USA) is a topical agent that had approval for treating tinea capitis, tinea cruris, tinea corporis, tinea pedis, moniliasis, and candidal intertrigo.</p>
        <p><bold>Clioquinol</bold> is a combination product with hydrocortisone (USA availability ?) This combination topical agent had approval to treat the same spectrum of dermatoses as iodoquinol:&#x000a0;tinea capitis, tinea cruris, tinea corporis, tinea pedis, moniliasis, and candidal intertrigo.</p>
        <p><bold>Potassium iodide,</bold> formulated as a saturated solution of potassium iodide (SSKI), has no official antifungal approvals;&#x000a0;but is used in the off-label treatment of both cutaneous and lymphocutaneous sporotrichosis.</p>
        <p><bold>Zinc pyrithione</bold> is not officially approved for antifungal purposes but has utilization as primary or adjunct therapy in the treatment of mycoses leading to hyperkeratotic skin conditions. A common off-label use is in the treatment of tinea (pityriasis) versicolor.</p>
      </sec>
      <sec id="article-17692.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p><bold>Polyene</bold>&#x000a0;antifungals (e.g., amphotericin B) bind to ergosterol, a steroid-alcohol unique to Fungi. The polyene-ergosterol complex creates pores in the fungal cell membrane, ultimately leading to electrolyte leakage, cell lysis, and cell death.<xref ref-type="bibr" rid="article-17692.r30">[30]</xref></p>
        <p><bold>Azole</bold> (e.g., miconazole)antifungal compounds are non-competitive inhibitors of the fungal enzyme lanosterol 14-alpha-demethylase, which is a rate-limiting enzyme in the fungal biosynthetic pathway of ergosterol.&#x000a0;This action destabilizes the fungal cell membrane, causing cell content leakage,&#x000a0;lysis,&#x000a0;and eventual death.<xref ref-type="bibr" rid="article-17692.r31">[31]</xref></p>
        <p><bold>Allylamines</bold> (e.g., terbinafine) inhibit the rate-limiting enzyme squalene epoxidase, responsible for&#x000a0;synthesizing precursors to ergosterol. This type of drug is another antifungal compound whose mechanism of action is the loss of cell membrane integrity.<xref ref-type="bibr" rid="article-17692.r32">[32]</xref></p>
        <p><bold>Echinocandins</bold> (e.g., caspofungin) inhibit the&#x000a0;fungal beta-(1,3)-D-glucan synthase, which is the enzyme responsible for synthesizing beta-(1,3)-D-glucan, a key component of&#x000a0;fungal cell walls. Losing this cell wall component leads to osmotic instability and cell death.<xref ref-type="bibr" rid="article-17692.r5">[5]</xref></p>
        <p><bold>Griseofulvin</bold> is a mitotic inhibitor, which binds to polymerized fungal microtubules, thereby&#x000a0;inhibiting the de-polymerization and leading to the failure of the fungal cell replication.<xref ref-type="bibr" rid="article-17692.r33">[33]</xref></p>
        <p><bold>Flucytosine</bold> is an antimetabolite compound absorbed into fungal cells via cytosine permease. Within the fungal cell, flucytosine gets&#x000a0;converted to 5-fluorouracil, which interferes with fungal RNA biosynthesis.<xref ref-type="bibr" rid="article-17692.r34">[34]</xref></p>
        <p><bold>Ciclopirox</bold> has a poorly understood mechanism of action but is believed to interfere with the structural integrity of the fungal cell membrane.<xref ref-type="bibr" rid="article-17692.r35">[35]</xref></p>
        <p><bold>Quinoline</bold> antifungal (e.g., clioquinol) compound derivatives also have a poorly understood mechanism of action.</p>
        <p><bold>Potassium Iodide</bold>&#x000a0;exerts its effects directly on <italic toggle="yes">Sporothrix</italic>
<italic toggle="yes">spp.</italic>, yet the exact mechanism of action remains unproven. Leading theories suggest that human polymorphonuclear cells convert potassium iodide to iodine via the action of myeloperoxidase. Iodine inhibits fungal germination and reduces structural integrity through the intracytosolic destruction of structural components.<xref ref-type="bibr" rid="article-17692.r36">[36]</xref></p>
        <p><bold>Zinc Pyrithione</bold>&#x000a0;has a poorly understood antifungal mechanism of action. Still, leading theories suggest this agent modifies fungal cellular membrane transport, leading to decreased concentrations of critical metabolic substrates, inhibiting protein synthesis, and&#x000a0;limiting ATP production.<xref ref-type="bibr" rid="article-17692.r37">[37]</xref> These metabolic changes are likely due to increased intracellular copper and iron-sulfur clusters, which lead to protein damage.<xref ref-type="bibr" rid="article-17692.r38">[38]</xref></p>
      </sec>
      <sec id="article-17692.s4" sec-type="Administration">
        <title>Administration</title>
        <p><bold>Amphotericin</bold>
<bold>B</bold> has several formulations, including amphotericin B, deoxycholate (d-AMB, or AMB-d), liposomal&#x000a0;amphotericin B (L-AMB),&#x000a0;amphotericin&#x000a0;B lipid complex (ABLC), and&#x000a0;amphotericin&#x000a0;B colloidal&#x000a0;dispersion (ABCD; not available in the United States); all approved indications are intravenous administration. Off-label administration of AMB-d is also given intraventricularly and as an irrigation solution.</p>
        <p><bold>Nystatin,</bold> the other polyene drug, is only approved for topical and oral "swish-and-swallow' applications. Nystatin is available as a powder, cream, and oral solution.</p>
        <p>The available preparations for systemic <bold>azole</bold> antifungals include tablets, capsules, oral solutions, and IV solutions. Azole drugs for local or topical use include powders, creams, ointments, gels, shampoos, and lozenges.</p>
        <p><bold>Terbinafine,</bold> from the allylamine class of antifungals, can be administered topically or orally, which is dependent on the fungal infection being local or systemic, respectively.&#x000a0;</p>
        <p><bold>Caspofungin, anidulafungin,</bold> and <bold>micafungin,</bold> the three main drugs in the echinocandin class, are all given intravenously as a reconstituted solution.&#x000a0;</p>
        <p><bold>Griseofulvin </bold>is only given orally as a tablet or suspension, which should be taken with a fatty meal to aid absorption.&#x000a0;</p>
        <p>To treat mycoses, <bold>flucytosine,</bold> also commonly known as 5-fluorocytosine, is almost always administered intravenously as a combination therapy with amphotericin B.</p>
        <p><bold>Ciclopirox</bold> is approved for topical use only but not for intracavitary or ophthalmic&#x000a0;applications. For these purposes, it is available as a compounded gel, cream, lacquer, shampoo, and suspension.&#x000a0;</p>
        <p>The <bold>quinolines</bold> iodoquinol and clioquinol had approval for topical administration. Clioquinol is combined with hydrocortisone in a compounded cream.</p>
        <p><bold>Potassium Iodide</bold> is most commonly administered topically as a saturated solution&#x000a0;of potassium iodide (SSKI)</p>
        <p><bold>Zinc Pyrithione,</bold> a compound used to treat topical fungal infections, is applied topically as a shampoo, a solid soap-like bar, or as a non-shampoo liquid.</p>
      </sec>
      <sec id="article-17692.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The systemic polyene antifungal&#x000a0;<bold>amphotericin B&#x000a0;</bold>(formulated as AMB-d, L-AMB, ABLC, and ABCD) has&#x000a0;potentially&#x000a0;severe adverse reactions. <bold>AMB-d</bold>&#x000a0;therapy carries the risk of hypotension, chills, headache, hypokalemia, hypomagnesemia, anemia, renal insufficiency, renal function&#x000a0;abnormalities, injection site pain, nausea, vomiting, rigors, and fever.<xref ref-type="bibr" rid="article-17692.r39">[39]</xref>
<bold>L-AMB</bold> therapy has decreased the incidence of renal&#x000a0;function abnormalities when compared to AMB-d, yet it still carries a risk of nephrotoxicity. The most common adverse events caused by L-AMB&#x000a0;therapy include hypertension, hypotension, tachycardia, localized phlebitis, chills, headache, skin rash, electrolyte abnormalities (hypokalemia, hypomagnesemia, hyponatremia, hyponatremia), hyperglycemia, abnormal liver function tests. <bold>ABLC</bold>&#x000a0;also carries a risk of nephrotoxicity, leading to increased serum creatinine, fever related to infusion, rigors, and chills, but these risks are less than treatment regimens, including AMB-d.</p>
        <p><bold>Nystatin</bold> is approved only for topical and oral "swish-and-swallow" applications because of severe systemic side effects. Adverse events related to topical nystatin include mild&#x000a0;contact dermatitis, with the most severe side effect being Stevens-Johnson syndrome. Oral "swish-and-swallow"&#x000a0;nystatin carries a lower risk of hypersensitivity reactions than topical formulations; there are also reports of diarrhea, nausea, vomiting, and abdominal pain.&#x000a0;</p>
        <p><bold>Azoles, </bold>while typically well-tolerated, frequently cause&#x000a0;nausea, vomiting, diarrhea, and abdominal pain. Hepatotoxicity (elevated liver function tests, hepatitis, cholestasis, and or fulminant&#x000a0;liver failure) is&#x000a0;a common adverse reaction associated with all azoles. Each of the azole drugs has unique adverse events as well:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Ketoconazole</bold> has associations with orthostatic hypotension, thrombocytopenia, pruritis, rash, myalgias, and a rare suppression of glucocorticoid production in the adrenal glands. Of note, ketoconazole also correlates with a significant amount more gastrointestinal distress than other azoles.</p>
          </list-item>
          <list-item>
            <p><bold>Fluconazole</bold> has been shown to cause mild headaches, dizziness, and alopecia in high doses.<xref ref-type="bibr" rid="article-17692.r40">[40]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Itraconazole</bold> has a triad of heart failure-like symptoms, hypertension, peripheral edema, and hypokalemia. There are reports of an increased risk of herpes zoster activation or reactivation, headache, dizziness,&#x000a0;and fatigue.</p>
          </list-item>
          <list-item>
            <p><bold>Voriconazole</bold> has the most numerous and unique of all the side effects in the azole class. These include vision changes, auditory and/or visual hallucinations, neurotoxicity, photosensitivity rash, photophobia, periostitis, cardiotoxicity, and alopecia.</p>
          </list-item>
          <list-item>
            <p><bold>Posaconazole</bold> most commonly causes thrombophlebitis secondary to&#x000a0;peripheral intravenous catheters, hypertension, hypotension, headache, rash, hypokalemia, and thrombocytopenia. Another reported adverse event is a&#x000a0;rare prolongation of the QTc interval.<xref ref-type="bibr" rid="article-17692.r41">[41]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Isavuconazole</bold> has&#x000a0;more severe gastrointestinal side effects than most of the other azoles. Other reported adverse events include a headache, hypokalemia, dyspnea, cough, and peripheral edema.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Miconazole</bold> has no reported serious adverse events but commonly causes contact dermatitis, burning/stinging, and pruritis at the application site.</p>
          </list-item>
          <list-item>
            <p><bold>Clotrimazole</bold> has no severe adverse reactions but commonly causes irritation, burning/stinging, pruritis, urticaria, and possible blistering at the application site.</p>
          </list-item>
        </list>
        <p><bold>Terbinafine,</bold> an allylamine, most commonly results in central nervous system side effects, with a headache being the most frequently reported symptom. Other manifestations of adverse events include but are not limited to rashes, diarrhea, dyspepsia, and upper respiratory inflammation or infection.</p>
        <p><bold>Echinocandins,</bold> like many other antifungal drugs, can result in hepatotoxicity.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Anidulafungin is associated</bold>&#x000a0;with hypotension, peripheral edema, insomnia, hypokalemia, hypomagnesemia, increased risk of urinary tract infections, dyspnea,&#x000a0;and fever.</p>
          </list-item>
          <list-item>
            <p><bold>Caspofungin</bold> can cause hypotension, peripheral edema, tachycardia, chills, headache, rash, anemia, localized phlebitis, respiratory failure, and infusion-related reactions.</p>
          </list-item>
          <list-item>
            <p><bold>Micafungin</bold> can cause phlebitis, anemia, transaminitis, hyperbilirubinemia, renal failure, and fever.</p>
          </list-item>
        </list>
        <p><bold>Griseofulvin</bold> has numerous potential adverse events, with the most commonly reported adverse events being rash and urticaria. More severe complications can occur and include an erythema multiforme-like drug reaction, skin photosensitivity, leukopenia (rare), granulocytopenia, and hepatotoxicity.</p>
        <p><bold>Flucytosine</bold> can cause adverse reactions to all body systems but is most commonly associated with the following: cardiovascular (cardiotoxicity, chest pain), central and peripheral nervous systems (confusion, headache hallucination, parkinsonian-like syndrome, peripheral neuropathy), dermatologic (pruritis, urticaria, rash), gastrointestinal (abdominal pain, nausea, vomiting, GI hemorrhage), hematologic (agranulocytosis, aplastic anemia, pancytopenia, eosinophilia), hepatic (acute hepatic injury/insufficiency /necrosis), and renal (acute kidney injury, renal failure).</p>
        <p><bold>Ciclopirox</bold>&#x000a0;has no significant reported serious adverse reactions, but common benign reactions include skin irritation/burning, contact dermatitis, and pruritis.</p>
        <p><bold>Quinolines</bold> (clioquinol and iodoquinol) most commonly have associations with dry skin, contact dermatitis, allergic reaction, rapid hair growth in areas the agent is applied, and folliculitis.</p>
        <p><bold>Potassium Iodide</bold> (as a saturated solution of potassium iodide) has several reported severe adverse reactions, including arrhythmias, GI bleeding, angioedema, parotitis, thyroid adenoma, and goiter. More frequent and less serious reactions include a possible metallic taste, urticaria, acne, cutaneous hemorrhage, numbness, and paresthesias.</p>
        <p><bold>Zinc Pyrithione</bold> has no reported serious adverse reactions and most commonly can cause mild skin irritation.&#x000a0;</p>
      </sec>
      <sec id="article-17692.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>All formulations of <bold>amphotericin</bold>
<bold>B (AMB-d, L-AMB, ABLC, ABCD)</bold> are contraindicated in patients with a known or likely hypersensitivity to amphotericin B or any components of the L-AMB, ABLC, or ABCD formulations.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>AMB-d</bold>&#x000a0;carries two FDA boxed warnings: 1) amphotericin B deoxycholate should be used for invasive, potentially life-threatening mycoses and avoided in non-invasive fungal&#x000a0;infections (oral thrush, esophageal candidiasis, and vaginal candidiasis in patients with neutrophil counts within normal limits); 2) risk of accidental overdose. The use of this agent should also exercise extreme caution in patients with renal impairment and or electrolyte abnormalities.</p>
          </list-item>
          <list-item>
            <p><bold>L-AMB, ABLC, and ABCD </bold>do not carry FDA boxed warnings but require caution in renal impairment.</p>
          </list-item>
        </list>
        <p><bold>Nystatin</bold> is contraindicated in patients with hypersensitivity&#x000a0;to the drug or any additional components in the dosage formulation.&#x000a0;</p>
        <p>All <bold>azoles</bold> should be avoided in patients with hypersensitivities to azole drugs or dosage form components and used with caution in patients with renal impairment/failure and or hepatic impairment/failure.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Fluconazole</bold> requires cautious administration in patients with electrolyte abnormalities, torsades de pointes, and or medical history, family history, and or current QTc prolongation.</p>
          </list-item>
          <list-item>
            <p><bold>Itraconazole</bold>&#x000a0;has an FDA boxed warning against the use in&#x000a0;treating onychomycosis&#x000a0;in patients with CHF. Itraconazole is contraindicated in pregnancy, left ventricular dysfunction, and current or active congestive heart failure. This drug should be used cautiously in patients with cystic fibrosis, cardiovascular disease, pulmonary disease, and the elderly.</p>
          </list-item>
          <list-item>
            <p><bold>Ketoconazole</bold> carries several FDA boxed warnings:</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>This agent should be used only when another effective antifungal, including azoles, cannot be tolerated or is not available</p>
          </list-item>
          <list-item>
            <p>This agent carries a significant risk of hepatotoxicity, even in patients without predisposing factors, and thus any treatment with ketoconazole should include close liver function monitoring.</p>
          </list-item>
          <list-item>
            <p>Ketoconazole has several contraindicated drug interactions that&#x000a0;may cause QTc prolongation by increasing concentrations of cisapride, disopyramide, dofetilide, dronedarone, methadone, quinidine, or ranolazine. Ketoconazole is a cytochrome P450 inhibitor.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Voriconazole</bold> is contraindicated in galactose malabsorption/intolerance, Lapp lactase deficiency, glucose malabsorption, uncorrected electrolyte abnormalities, and pregnancy. Clinicians should use this agent with caution in patients with a medical or family history of QTc prolongation, history of torsades de pointes, and or hematologic malignancy.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Isavuconazole</bold> is contraindicated in patients with familial short QTc syndrome and should be used with caution in patients with hematologic malignancies.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Posaconazole</bold> is contraindicated in pregnancy. Caution is advisable in patients with electrolyte abnormalities, renal insufficiency, cardiomyopathy, torsades de pointes, or medical history/family history/congenital prolonged QTc interval.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Terbinafine</bold> should be utilized with caution or avoided in patients with hypersensitivity&#x000a0;reactions, depression, gastrointestinal issues, liver failure, and immune suppression&#x000a0;secondary to hematologic effects.</p>
        <p>All <bold>echinocandins</bold> are contraindicated in patients with hypersensitivities to any of the echinocandin drugs or dosage form components. Caspofungin should be used with caution in hepatic impairment.</p>
        <p>Treatment with <bold>griseofulvin</bold> should include considerations for potential adverse events in susceptible patients and those with existing disease states; particularly&#x000a0;patients with a hypersensitivity to griseofulvin, a hypersensitivity to penicillins&#x000a0;(there&#x000a0;is a possible cross-reaction between penicillins and griseofulvin), hepatic failure, patients with known porphyrias, and patients that are pregnant or nursing.</p>
        <p><bold>Flucytosine</bold> carries an FDA boxed warning that this agent should be used with extreme caution in renal impairment and that hematologic, hepatic, and renal function should have close monitoring. This agent is contraindicated in patients with hypersensitivity to this drug or its components, first trimester pregnancies, and breastfeeding women. Caution is advisable with this agent in patients with renal impairment, hepatic impairment, bone marrow depression, and pregnant patients in their second or third trimester.</p>
        <p>The <bold>quinolines</bold> iodoquinol and clioquinol are contraindicated in patients with hypersensitivities to the drugs or their components.</p>
        <p>Antifungals, which are utilized only as topical agents, including <bold>ciclopirox, potassium iodide,</bold> and <bold>zinc pyrithione,</bold> should be avoided in patients with hypersensitivities to these agents.</p>
      </sec>
      <sec id="article-17692.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p><bold>Polyenes</bold> have no supporting evidence or indication at this time to support the utilization of therapeutic drug level monitoring (TDM) in patients treated with AMB-d, L-AMB, and ABLC.<xref ref-type="bibr" rid="article-17692.r42">[42]</xref> All patients receiving any formulations of amphotericin B should have BUN and creatinine assessed at baseline then frequently after; additionally, CBC, electrolytes, and LFTs require monitoring. Nystatin does not have supporting evidence for TDM or routine laboratory monitoring.</p>
        <p><bold>Azole</bold> antifungals that are generally indicated for therapeutic drug concentration monitoring (TDM) all come from the triazole sub-class: itraconazole, voriconazole, posaconazole.<xref ref-type="bibr" rid="article-17692.r42">[42]</xref> Laboratory monitoring is necessary for the use of fluconazole, isavuconazonium sulfate, and ketoconazole; there is no current monitoring indication for clotrimazole or miconazole.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients receiving <bold>itraconazole</bold> should receive TDM. Therapeutic drug concentrations are between 0.5 to 1 mcg/mL. Trough concentrations should be assessed after the first administration around the time of steady-state (approximately 5 to 7 days) and then re-assessed just before each consecutive dose.&#x000a0;There is an increased likelihood of adverse reactions if concentrations are greater than 5 mcg/mL. Additionally, LFTs should undergo an assessment at baseline and be periodically evaluated in patients with hepatic impairment or treatment regimens lasting longer than one month.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Therapeutic drug concentrations in <bold>voriconazole</bold>-containing&#x000a0;regimens have a recommended trough between 1 to 1.5 mcg/mL; this requires assessment at the time to steady-state (variable, about 4 to 7 days) and before subsequent administrations. Toxic concentrations are concentrations greater than 5 mcg/mL, at which CNS toxicity tends to occur. Monitoring includes LFTs, creatinine, and electrolytes (including magnesium and calcium) at baseline and frequently after that (every one week for LFTs for four weeks, then every four weeks subsequently). Lipase should undergo assessment if a patient has a risk of pancreatitis. Finally, an ophthalmic exam is necessary for patients receiving voriconazole for greater than 28 days.&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Posaconazole</bold> has therapeutic drug concentrations of greater than 0.7 mcg/mL in prophylaxis and greater than 1.0 mcg/mL in salvage therapy. Trough&#x000a0;serum concentration should get measured on day seven and before doses or following dose adjustments. Creatinine, electrolytes (including magnesium and calcium), and LFTs should be checked at baseline, then frequently during treatment.</p>
          </list-item>
          <list-item>
            <p>Monitoring parameters for <bold>fluconazole</bold> entail checking creatinine at baseline and monitoring LFTs.</p>
          </list-item>
          <list-item>
            <p>The use of <bold>isavuconazonium sulfate</bold> requires checking LFTs at baseline, then periodically during treatment.</p>
          </list-item>
          <list-item>
            <p>Monitoring of <bold>ketoconazole</bold>-containing&#x000a0;regimens should include LFTs at baseline and during therapy, with ALT being checked weekly. The adrenal function requires monitoring if the patient is at risk of adrenal insufficiency.&#x000a0;</p>
          </list-item>
        </list>
        <p><bold>Terbinafine&#x000a0;</bold>has no supporting evidence to suggest that&#x000a0;TDM is necessary for its utilization in prophylaxis, treatment, or toxicity. Monitoring creatinine and LFTs is, however, an indication at baseline.&#x000a0;Immunodeficient patients receiving terbinafine for greater than six weeks should have a CBC checked.</p>
        <p><bold>Griseofulvin</bold> does not currently have supporting evidence for TDM, but laboratory monitoring includes BUN, creatinine, CBC, and LFTs.</p>
        <p>Patients on <bold>echinocandin</bold> therapy should be regularly monitored for hepatotoxicity via hepatic aminotransferases (AST, ALT), with the additional consideration of alkaline phosphatase.&#x000a0;There is currently no supporting evidence for TDM. Micafungin regimens should include BUN and creatinine in routine laboratory monitoring.</p>
        <p>Patients receiving <bold>flucytosine</bold>-containing&#x000a0;combination therapy require TDM. Patients should have serum concentration measured 2 to 4 hours after each dose; the trough concentration should be between 20 to 40 mcg/L (some sources state 50 to 100 mcg/mL). Toxic concentrations occur when serum drug concentrations exceed 100 mcg/mL. Other indications for TDM in flucytosine therapy include when a drug with a known drug interaction is started or stopped, when adherence for oral therapy is uncertain, or when manifestations of toxicity occur.<xref ref-type="bibr" rid="article-17692.r42">[42]</xref></p>
      </sec>
      <sec id="article-17692.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Pragmatic management of mycoses is dependent on the interprofessional healthcare team characterizing the fungal infection as discussed in the introduction, then selecting the most effective antifungal treatment regimen; this requires a&#x000a0;strong understanding of public health/epidemiology, medical microbiology/mycology, clinical pharmacology, and healthcare infrastructure which dictates the application of the first three. There is currently a diverse and effective arsenal of antifungal agents. Still, the alarming global rise in drug-resistant&#x000a0;fungi warrants judicious antifungal prescribing by clinicians, combinatorial&#x000a0;strategies,&#x000a0;utilization of antifungal adjuvants, and continued antifungal drug discovery/development.</p>
        <p>Judicious prescribing begins with the healthcare team selecting the proper regimen based on culture and sensitivity&#x000a0;data, patient history, and socioeconomic factors. Providers should work closely with pharmacists, and when appropriate, public health officials to provide therapy that appropriately treats infections. Nurses can also assess patient adherence, help administer the drug in the inpatient setting, answer patient questions, and watch for adverse drug reactions. The ultimate goal is to provide antifungal therapy without unnecessarily creating drug-resistant&#x000a0;organisms, limiting adverse events, and reducing drug-drug interactions. Antifungal stewardship is essential to preserve the effectiveness of current antifungal agents.<xref ref-type="bibr" rid="article-17692.r43">[43]</xref>&#x000a0;[Level 5]</p>
        <p>Combination therapy comprises treatment regimens that include multiple antifungals from different classes and antifungal agents combined with non-antifungal agents. Non-antifungal drug targets include heat shock proteins, calcineurin, lysine acetyltransferase, lysine deacetylase, protein kinase C, and fungal sphingolipids.<xref ref-type="bibr" rid="article-17692.r44">[44]</xref>&#x000a0;[Level 5]&#x000a0;</p>
        <p>Antifungal adjuvants can enhance and or extend the efficacy of existing antifungal regimens and limit resistance. Some of these encouraging adjuvants could eventually be the standard of care in antifungal-adjuvant combination therapy. The potential adjuvants include drugs with widely variable mechanisms of action like cyclosporin A, deferasirox, FK506, tamoxifen, and sertraline.<xref ref-type="bibr" rid="article-17692.r45">[45]</xref>&#x000a0;[Level 4]</p>
        <p>Antifungal drug discovery has been bolstered by the Orphan Drug Act (1983) and, more recently, the Generating Antibiotic Incentives Now (GAIN) Act (2012). These policies incentivize pharmaceutical companies and researchers to pursue new leads and add to the existing collection of antifungals. The increasing prevalence of drug-resistant fungal diseases presents a unique challenge to antifungal drug discovery. Yet, there are several promising new drug/class pipelines,&#x000a0;theoretical fungal vaccines,&#x000a0;and&#x000a0;the opportunity to generate compounds to inhibit resistance.<xref ref-type="bibr" rid="article-17692.r46">[46]</xref><xref ref-type="bibr" rid="article-17692.r47">[47]</xref><xref ref-type="bibr" rid="article-17692.r48">[48]</xref> [Level 5]</p>
        <p>The caveat to all of these potentially promising leads in new&#x000a0;drugs and drug classes is the time it takes from discovery to dispensing a new medication, estimated to be roughly 12 years.<xref ref-type="bibr" rid="article-17692.r49">[49]</xref> This cycle, unfortunately, leads to the need for ancillary and interim solutions, which include judicious prescribing to limit resistance, combinatorial therapy, and antifungal adjuvant therapies.</p>
      </sec>
      <sec id="article-17692.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17692&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17692">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17692/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17692">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-17692.s10">
        <title>References</title>
        <ref id="article-17692.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <chapter-title>Spectrum of Mycoses</chapter-title>
            <person-group person-group-type="editor">
              <name>
                <surname>Baron</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <source>Medical Microbiology</source>
            <edition>4th</edition>
            <publisher-name>University of Texas Medical Branch at Galveston</publisher-name>
            <publisher-loc>Galveston (TX)</publisher-loc>
            <year>1996</year>
            <pub-id pub-id-type="pmid">21413276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lai</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Hsueh</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Current challenges in the management of invasive fungal infections.</article-title>
            <source>J Infect Chemother</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>77</fpage>
            <page-range>77-85</page-range>
            <pub-id pub-id-type="pmid">18622668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Park</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Wannemuehler</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Marston</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Govender</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Chiller</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS.</article-title>
            <source>AIDS</source>
            <year>2009</year>
            <month>Feb</month>
            <day>20</day>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>525</fpage>
            <page-range>525-30</page-range>
            <pub-id pub-id-type="pmid">19182676</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Current concepts in antifungal pharmacology.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>86</volume>
            <issue>8</issue>
            <fpage>805</fpage>
            <page-range>805-17</page-range>
            <pub-id pub-id-type="pmid">21803962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grover</surname>
                <given-names>ND</given-names>
              </name>
            </person-group>
            <article-title>Echinocandins: A ray of hope in antifungal drug therapy.</article-title>
            <source>Indian J Pharmacol</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>42</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-11</page-range>
            <pub-id pub-id-type="pmid">20606829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r6">
          <label>6</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Fosses Vuong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hollingshead</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Waymack</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <chapter-title>Aspergillosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">29489184</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r7">
          <label>7</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Mada</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Jamil</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Alam</surname>
                <given-names>MU</given-names>
              </name>
            </person-group>
            <chapter-title>Cryptococcus</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>7</day>
            <pub-id pub-id-type="pmid">28613714</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spampinato</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents.</article-title>
            <source>Biomed Res Int</source>
            <year>2013</year>
            <volume>2013</volume>
            <fpage>204237</fpage>
            <pub-id pub-id-type="pmid">23878798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r9">
          <label>9</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Miceli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krishnamurthy</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <chapter-title>Blastomycosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">28723016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r10">
          <label>10</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Karray</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McKinney</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <chapter-title>Tinea Versicolor</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">29494106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r11">
          <label>11</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Akram</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Koirala</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Coccidioidomycosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>2</month>
            <day>25</day>
            <pub-id pub-id-type="pmid">28846274</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nucci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Nou&#x000e9;r</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Capone</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anaissie</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nucci</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Fusariosis.</article-title>
            <source>Semin Respir Crit Care Med</source>
            <year>2015</year>
            <month>Oct</month>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>706</fpage>
            <page-range>706-14</page-range>
            <pub-id pub-id-type="pmid">26398537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Akram</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Koirala</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Histoplasmosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">28846361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marques</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Paracoccidioidomycosis: epidemiological, clinical, diagnostic and treatment up-dating.</article-title>
            <source>An Bras Dermatol</source>
            <year>2013</year>
            <season>Sep-Oct</season>
            <volume>88</volume>
            <issue>5</issue>
            <fpage>700</fpage>
            <page-range>700-11</page-range>
            <pub-id pub-id-type="pmid">24173174</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r15">
          <label>15</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Kurien</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sugumar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chandran</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <chapter-title>Chromoblastomycosis</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">29261968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barros</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>de Almeida Paes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Schubach</surname>
                <given-names>AO</given-names>
              </name>
            </person-group>
            <article-title>Sporothrix schenckii and Sporotrichosis.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>633</fpage>
            <page-range>633-54</page-range>
            <pub-id pub-id-type="pmid">21976602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weitzman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Summerbell</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>The dermatophytes.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>1995</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>240</fpage>
            <page-range>240-59</page-range>
            <pub-id pub-id-type="pmid">7621400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Andes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Calandra</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Filler</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kullberg</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Ostrosky-Zeichner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Reboli</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Rex</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>JD</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2009</year>
            <month>Mar</month>
            <day>01</day>
            <volume>48</volume>
            <issue>5</issue>
            <fpage>503</fpage>
            <page-range>503-35</page-range>
            <pub-id pub-id-type="pmid">19191635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perfect</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Dismukes</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Dromer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Graybill</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hamill</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Lortholary</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Powderly</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Sorrell</surname>
                <given-names>TC</given-names>
              </name>
            </person-group>
            <article-title>Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.</article-title>
            <source>Clin Infect Dis</source>
            <year>2010</year>
            <month>Feb</month>
            <day>01</day>
            <volume>50</volume>
            <issue>3</issue>
            <fpage>291</fpage>
            <page-range>291-322</page-range>
            <pub-id pub-id-type="pmid">20047480</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wheat</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Freifeld</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Kleiman</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Baddley</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>McKinsey</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Loyd</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>CA</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2007</year>
            <month>Oct</month>
            <day>01</day>
            <volume>45</volume>
            <issue>7</issue>
            <fpage>807</fpage>
            <page-range>807-25</page-range>
            <pub-id pub-id-type="pmid">17806045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chapman</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Dismukes</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Proia</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Bradsher</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Threlkeld</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>CA</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2008</year>
            <month>Jun</month>
            <day>15</day>
            <volume>46</volume>
            <issue>12</issue>
            <fpage>1801</fpage>
            <page-range>1801-12</page-range>
            <pub-id pub-id-type="pmid">18462107</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kauffman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bustamante</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
              <collab>Infectious Diseases Society of America</collab>
            </person-group>
            <article-title>Clinical practice guidelines for the management of sporotrichosis: 2007 update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2007</year>
            <month>Nov</month>
            <day>15</day>
            <volume>45</volume>
            <issue>10</issue>
            <fpage>1255</fpage>
            <page-range>1255-65</page-range>
            <pub-id pub-id-type="pmid">17968818</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thursky</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Playford</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Seymour</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Sorrell</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>DH</given-names>
              </name>
              <name>
                <surname>Guy</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Gilroy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Recommendations for the treatment of established fungal infections.</article-title>
            <source>Intern Med J</source>
            <year>2008</year>
            <month>Jun</month>
            <volume>38</volume>
            <issue>6b</issue>
            <fpage>496</fpage>
            <page-range>496-520</page-range>
            <pub-id pub-id-type="pmid">18588522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galgiani</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Ampel</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Blair</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Catanzaro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Geertsma</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hoover</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Kusne</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lisse</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>MacDonald</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Meyerson</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Raksin</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Siever</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Sunenshine</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Theodore</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>2016 Infectious Diseases Society of America (IDSA) Clinical Practice Guideline for the Treatment of Coccidioidomycosis.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Sep</month>
            <day>15</day>
            <volume>63</volume>
            <issue>6</issue>
            <fpage>e112</fpage>
            <page-range>e112-46</page-range>
            <pub-id pub-id-type="pmid">27470238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patterson</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Denning</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Hadley</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Herbrecht</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kontoyiannis</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Marr</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Morrison</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Steinbach</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Walsh</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wingard</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>Aug</month>
            <day>15</day>
            <volume>63</volume>
            <issue>4</issue>
            <fpage>e1</fpage>
            <page-range>e1-e60</page-range>
            <pub-id pub-id-type="pmid">27365388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sahoo</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Mahajan</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review.</article-title>
            <source>Indian Dermatol Online J</source>
            <year>2016</year>
            <season>Mar-Apr</season>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>77</fpage>
            <page-range>77-86</page-range>
            <pub-id pub-id-type="pmid">27057486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rogers</surname>
                <given-names>TR</given-names>
              </name>
            </person-group>
            <article-title>Treatment of zygomycosis: current and new options.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>61 Suppl 1</volume>
            <fpage>i35</fpage>
            <page-range>i35-40</page-range>
            <pub-id pub-id-type="pmid">18063603</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Savin</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and treatment of tinea versicolor.</article-title>
            <source>J Fam Pract</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>43</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-32</page-range>
            <pub-id pub-id-type="pmid">8708621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lortholary</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez-Ruiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perfect</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>The current treatment landscape: other fungal diseases (cryptococcosis, fusariosis and mucormycosis).</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>71</volume>
            <issue>suppl 2</issue>
            <fpage>ii31</fpage>
            <page-range>ii31-ii36</page-range>
            <pub-id pub-id-type="pmid">27880667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Prasad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Rawal</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Antifungals: Mechanism of Action and Drug Resistance.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2016</year>
            <volume>892</volume>
            <fpage>327</fpage>
            <page-range>327-349</page-range>
            <pub-id pub-id-type="pmid">26721281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ghannoum</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Rice</surname>
                <given-names>LB</given-names>
              </name>
            </person-group>
            <article-title>Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>501</fpage>
            <page-range>501-17</page-range>
            <pub-id pub-id-type="pmid">10515900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birnbaum</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Pharmacology of the allylamines.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>23</volume>
            <issue>4 Pt 2</issue>
            <fpage>782</fpage>
            <page-range>782-5</page-range>
            <pub-id pub-id-type="pmid">2229523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elewski</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of systemic antifungal agents.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1993</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5 Pt 1</issue>
            <fpage>S28</fpage>
            <page-range>S28-S34</page-range>
            <pub-id pub-id-type="pmid">8496409</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waldorf</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Polak</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of action of 5-fluorocytosine.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1983</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-85</page-range>
            <pub-id pub-id-type="pmid">6338821</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Niewerth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kunze</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Seibold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schaller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Korting</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Hube</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2003</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>6</issue>
            <fpage>1805</fpage>
            <page-range>1805-17</page-range>
            <pub-id pub-id-type="pmid">12760852</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hiruma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kagawa</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Ultrastructure of Sporothrix schenckii treated with iodine-potassium iodide solution.</article-title>
            <source>Mycopathologia</source>
            <year>1987</year>
            <month>Feb</month>
            <volume>97</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-7</page-range>
            <pub-id pub-id-type="pmid">3574432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chandler</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Segel</surname>
                <given-names>IH</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of the antimicrobial action of pyrithione: effects on membrane transport, ATP levels, and protein synthesis.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1978</year>
            <month>Jul</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-8</page-range>
            <pub-id pub-id-type="pmid">28693</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reeder</surname>
                <given-names>NL</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Youngquist</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Schwartz</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Rust</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Saunders</surname>
                <given-names>CW</given-names>
              </name>
            </person-group>
            <article-title>The antifungal mechanism of action of zinc pyrithione.</article-title>
            <source>Br J Dermatol</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>165 Suppl 2</volume>
            <fpage>9</fpage>
            <page-range>9-12</page-range>
            <pub-id pub-id-type="pmid">21919897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laniado-Labor&#x000ed;n</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cabrales-Vargas</surname>
                <given-names>MN</given-names>
              </name>
            </person-group>
            <article-title>Amphotericin B: side effects and toxicity.</article-title>
            <source>Rev Iberoam Micol</source>
            <year>2009</year>
            <month>Dec</month>
            <day>31</day>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>223</fpage>
            <page-range>223-7</page-range>
            <pub-id pub-id-type="pmid">19836985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pappas</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Kauffman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Perfect</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>McKinsey</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Bamberger</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Hamill</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharkey</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Chapman</surname>
                <given-names>SW</given-names>
              </name>
              <name>
                <surname>Sobel</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Alopecia associated with fluconazole therapy.</article-title>
            <source>Ann Intern Med</source>
            <year>1995</year>
            <month>Sep</month>
            <day>01</day>
            <volume>123</volume>
            <issue>5</issue>
            <fpage>354</fpage>
            <page-range>354-7</page-range>
            <pub-id pub-id-type="pmid">7625624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mohr</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Ostrosky-Zeichner</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Current options in antifungal pharmacotherapy.</article-title>
            <source>Pharmacotherapy</source>
            <year>2008</year>
            <month>May</month>
            <volume>28</volume>
            <issue>5</issue>
            <fpage>614</fpage>
            <page-range>614-45</page-range>
            <pub-id pub-id-type="pmid">18447660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ashbee</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Barnes</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Gorton</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>WW</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2014</year>
            <month>May</month>
            <volume>69</volume>
            <issue>5</issue>
            <fpage>1162</fpage>
            <page-range>1162-76</page-range>
            <pub-id pub-id-type="pmid">24379304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richardson</surname>
                <given-names>MD</given-names>
              </name>
            </person-group>
            <article-title>An introduction to antifungal stewardship.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2016</year>
            <month>Nov</month>
            <volume>71</volume>
            <issue>suppl 2</issue>
            <fpage>ii3</fpage>
            <pub-id pub-id-type="pmid">27880663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spitzer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>GD</given-names>
              </name>
            </person-group>
            <article-title>Combinatorial strategies for combating invasive fungal infections.</article-title>
            <source>Virulence</source>
            <year>2017</year>
            <month>Feb</month>
            <day>17</day>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>169</fpage>
            <page-range>169-185</page-range>
            <pub-id pub-id-type="pmid">27268286</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butts</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Palmer</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>PD</given-names>
              </name>
            </person-group>
            <article-title>Antifungal adjuvants: Preserving and extending the antifungal arsenal.</article-title>
            <source>Virulence</source>
            <year>2017</year>
            <month>Feb</month>
            <day>17</day>
            <volume>8</volume>
            <issue>2</issue>
            <fpage>198</fpage>
            <page-range>198-210</page-range>
            <pub-id pub-id-type="pmid">27459018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Calderone</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Gay-Andrieu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Groutas</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Weerawarna</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Prasad</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Alex</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Antifungal drug discovery: the process and outcomes.</article-title>
            <source>Future Microbiol</source>
            <year>2014</year>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>791</fpage>
            <page-range>791-805</page-range>
            <pub-id pub-id-type="pmid">25046525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jampilek</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>How can we bolster the antifungal drug discovery pipeline?</article-title>
            <source>Future Med Chem</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>1393</fpage>
            <page-range>1393-7</page-range>
            <pub-id pub-id-type="pmid">27464242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reales-Calder&#x000f3;n</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Molero</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gil</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>The fungal resistome: a risk and an opportunity for the development of novel antifungal therapies.</article-title>
            <source>Future Med Chem</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>8</volume>
            <issue>12</issue>
            <fpage>1503</fpage>
            <page-range>1503-20</page-range>
            <pub-id pub-id-type="pmid">27485839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17692.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Butts</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krysan</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Antifungal drug discovery: something old and something new.</article-title>
            <source>PLoS Pathog</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>8</volume>
            <issue>9</issue>
            <fpage>e1002870</fpage>
            <pub-id pub-id-type="pmid">22969422</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
